

August 07, 2022

| | |
|---|--|
| DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213 | Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No.C/1, 'G'Block, Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI |
|---|--|

Dear Sir/Madam,

Subject: Q1 & FY23 Press Release

Please find enclosed a copy of the Press Release for the quarter ended June 30, 2022.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

For Rossari Biotech Limited



Parul Gupta

Company Secretary & Compliance Officer

Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company)

Regd. Office : 201 A & B, Akruti Corporate Park, Next to GE Gardens, LBS Marg, Kanjurmarg (W), Mumbai - 400078, India. **T** +91-22-6123 3800 **F** +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/111/1, Kumbharwadi, Village Naroli, Dadra & Nagar Haveli (U.T.), Silvassa - 396 235, India. **T** 0260 - 669 3000

E info@rossarimail.com **W** www.rossari.com

CIN: L24100MH2009PLC194818



Rossari Biotech Limited

Corporate Office: 201 A & B Ackruti Corporate Park LBS Marg Next to G. E. Gardens, Kanjurmarg West,
Mumbai, Maharashtra 400078

Rossari Biotech announces Q1 FY23 results

Q1 FY23

**Revenues at Rs. 434.71 Cr,
EBITDA improves by 11% Q-o-Q to Rs. 57.73 Cr
PAT at Rs. 28.68 Cr, higher by 19% Q-o-Q**

Mumbai, August 06, 2022: Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended June 30, 2022.

Consolidated: Q1 FY23 performance overview compared with Q4 FY22

- Revenues from operations stood at Rs. 434.71 crore as against Rs. 438.93 crore
- EBITDA at Rs. 57.73 crore as against Rs. 52.31 crore
 - EBITDA margin at 13.3% as against 11.9%
- PAT stood at Rs. 28.68 crore as against Rs. 24.08 crore
- EPS (Diluted) stood at Rs. 5.18 as against Rs. 4.35

Standalone: Q1 FY23 performance overview compared with Q4 FY22

- Revenues from operations stood at Rs. 233.73 crore as against Rs. 261.64 crore
- EBITDA at Rs. 27.06 crore as against Rs. 27.46 crore
 - EBITDA margin at 11.6% as against 10.5%
- PAT stood at Rs. 15.36 crore as against Rs. 16.87 crore
- EPS (Diluted) stood at Rs. 2.78 as against Rs. 3.05

Commenting on the performance for the quarter, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said

“We have delivered steady performance during the quarter despite a subdued demand macro-environment. On a standalone basis, we marked growth of 15% on Y-o-Y basis. Our acquired businesses, Unitop, Tristar, and Romakk Chemicals, too, delivered improved performance in the quarter. Overall, on a consolidated basis, our total revenue from operations stood at Rs. 435 crores.

On the profitability front, we delivered healthy margins during the quarter backed by price increases and softening of raw material prices. Our gross margins grew by 246 bps and EBITDA margins grew by 136 bps Q-o-Q. Currently, we are witnessing signs of tapering of key input prices as well as stabilising supply chains. A normalised operating environment, along with our cost optimisation initiatives should enable us to improve margins, going ahead.

In the past many years, we have seeded multiple new business lines with an emphasis towards sustainability and environment-friendliness. These product niches have been well appreciated by our customers and we have seen this reflect in the growth of our overall customer base. Our endeavour is to further amplify our leadership position and strengthen foothold across product categories.

There is ample growth potential for all our business verticals and acquired businesses in both the domestic and international markets and we are optimistic of tapping upon these opportunities, going forward. In a stabilised environment, we look forward to delivering strong and sustainable growth across verticals.

The Specialty Chemicals industry in India is fast progressing with multiple strong growth prospects ahead. With a strong balance sheet, adequate manufacturing capacities and a solid product portfolio, we are well-poised to capitalize on the upcoming opportunities in this space.”

Note:

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) EPS not annualized
- 3) Rossari completed the acquisition of 65% equity shares of Unitop Chemicals Private Limited (“Unitop”) w.e.f August 26, 2021, of 76% equity shares of Tristar Intermediates Private Limited (“Tristar”) w.e.f September 1, 2021 and of 50.1% equity shares of Romakk Chemicals Private Limited (“Romakk”) w.e.f November 25, 2021. Accordingly, results for the quarter ended 30th June, 2022 and quarter and year ended 31st March, 2022 includes results of Unitop and Tristar for the relevant periods, as applicable and hence the results for current quarter and quarter ended June 30, 2021 (corresponding quarter) are not comparable with the previous periods.

About Rossari Biotech Limited:

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

For more information, please visit www.rossari.com OR contact:

Manasi Nisal

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: manasi.nisal@rossarimail.com

Anoop Poojari / Aesha Shah

CDR India

Tel: +91 98330 90434 / 9867250569

Email: anoop@cdr-india.com /
aesha@cdr-india.com

DISCLAIMER:

Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.